Treatment of advanced ovarian cancer with sequential combination chemotherapy
β Scribed by Thomas W. Griffin; Richard A. Hunter; Andrew I. Cederbaum; Won K. Tak; Allen D. Ward; Joel H. Schwartz; Thomas F. Halpin; Gary M. Strauss; Rowland N. Meyer; Marcia K. Liepman; Harry L. Greene; Mary E. Costanza
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 517 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Seventyβtwo women with metastatic breast cancer were treated with multipleβagent chemotherapy. Fifty women were treated with 5 drugs in combination: 5βFU, methotrexate, vincristine, cytoxan, and prednisone; 22 were treated with the combination of 3 drugs: 5βFU, cytoxan, and prednisone.
Combination chemotherapy with Adriamycin-cyclophosphamide was employed after surgical treatment in 60 women with Stage 111-IV ovarian adenocarcinoma. Of 53 evaluable patients, objective response was noted in 34 of 41 (83%) without prior cytotoxic therapy but in only two of 12 (17%) who had failed a
Twenty-eight patients with lung cancer, 26 with extensive disease, were treated with the drugs Cytoxan (Cyt) and methotrexate (MTX). The schedule was based on cellular kinetics concepts. Initial therapy was with Cyt 1.1 g/m2 (intravenously) followed by MTX 20 mg/m2 orally, twice weekly, started 9 da